Junlian Healthcare Portfolio Highlights: Gene Editing Breakthroughs and Ophthalmic Device Leadership Featured in October 2025 Update

RapidGen Completes $75 Million Series A Financing, Initiates Comprehensive Strategic Partnerships with Tibet Rhodiola Pharmaceutical Holding Company and CMS

On September 30, 2025, PrecisionGene Therapeutics (Suzhou) Co., Ltd. ("PrecisionGene Therapeutics" hereinafter) announced the completion of a Series A financing round totaling US$75 million. The company also launched a comprehensive strategic partnership with the investors from this round: Tibet Rhodiola Pharmaceutical Holding Company (600211.SH) and CHINA MEDICAL SYSTEM HOLDINGS LIMITED (867.HK; 8A8.SG). Founded in 2021, PrecisionGene Therapeutics focuses on the development of in vivo gene-editing drugs based on non-viral delivery systems such as LNPs. The core team at PrecisionGene Therapeutics has extensive experience across the entire biopharmaceutical lifecycle, establishing an industry-grade end-to-end in vivo gene-editing technology platform. They have developed a series of key patented technologies for gene editing and delivery, including the novel base editor ARTbase-A1™, which has been granted patents in both China and the United States. PrecisionGene Therapeutics has built a product pipeline targeting hereditary rare diseases and difficult-to-treat common conditions. ART001, its product for transthyretin amyloidosis (ATTR), became the first LNP-based in vivo gene-editing product in China to enter human clinical trials (IIT) in August 2023. In August 2024, it was the first of its kind in China to receive FDA clinical trial authorization in the U.S., and by May 2025, it had become the first in China to obtain Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA. ART001 is currently in Phase II clinical trials. Human data from ART001 subjects, including IIT trials, has been observed for up to two years, showing stable efficacy and demonstrating the potential for "a single dose for life." ART002, its product for heterozygous familial hypercholesterolemia (HeFH), became the world’s first in its class to achieve therapeutic saturation in humans and effectively lower LDL-C levels in patients with extremely high baselines in April 2025, with human subject data observed for up to 48 weeks. Both ART001 and ART002 have shown excellent safety profiles, without infusion-related reactions, including fever, frequently seen in similar products domestically and internationally. No off-target signals were detected even at multi-fold saturated doses. With their combined efficacy and safety, ART001 and ART002 both demonstrate best-in-class potential.

TowardPi Medical Recently Completed E+ Round of Financing

TowardPi Medical recently completed its E+ round of financing. This follows the company's E-round financing earlier this year, marking the second financing deal completed within the year. TowardPi Medical’s core technology originates from Tsinghua University’s scientific research transformation. Its product lines cover ophthalmic OCT, surgical microscopes, ultra-widefield cameras, biometers, phacoemulsification and vitrectomy machines, femtosecond lasers, and ophthalmic AI systems, with products winning the second prize of the Beijing Science and Technology Progress Award. Relying on the company’s robust full in-house R&D capabilities for core components and excellent market reputation, during the first three quarters of 2025, according to publicly available procurement data on ophthalmic equipment tenders, TowardPi and the imported brand Zeiss became the only two brands in China to rank in the top five market shares across four major product lines (surgical microscopes, OCT, ultra-widefield cameras, and biometers). In the first three quarters of 2025, TowardPi Medical's ophthalmic OCT products retained their "double first" position in total bid value and total units, achieving a market share of 38.7% in bid value, further widening their leading advantage. In overseas markets, since obtaining CE certification in 2024, TowardPi’s OCT overseas sales quickly surpassed 100 units, with its market share entering the top five in the European market, and its average selling price ranking first in Europe. As the company’s second growth curve, ophthalmic surgical microscopes ranked fourth in total bid value in the industry for the first three quarters of this year (the top three were all imported brands), with an average bid price of 4.529 million yuan, ranking first in the industry. Among these, the “Boyun” series, representing high-end domestically produced models, made history by entering the top ten in the detailed model rankings for the first time. Meanwhile, ultra-widefield fundus cameras and biometers ranked fourth and third respectively in total bid value in the industry, successfully fulfilling their product mission of completing the pipeline. The R&D progress of integrated phacoemulsification-vitrectomy machines, neurosurgical microscopes, and femtosecond laser cataract surgery systems is proceeding steadily, with expected launches over the next 2-3 years.

Innovent's Masitide Head-to-Head Semaglutide Phase III Clinical Trial DREAMS-3 Achieves Primary Endpoint

October 27, 2025, San Francisco, USA, and Suzhou, China — Innovent Biologics, Inc. (HKEX stock code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs in major disease areas such as oncology, autoimmune disorders, metabolic diseases, cardiovascular conditions, and ophthalmology, announced today that the fourth Phase III clinical trial (DREAMS-3) of its glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, mazdutide (research code: IBI362), has met its primary endpoint. The study results demonstrated that in Chinese subjects with type 2 diabetes and obesity, at week 32, the proportion of subjects in the mazdutide group achieving HbA1c <7.0% and ≥10% weight loss from baseline was 48.0%, significantly superior to the semaglutide group (21.0%, P-value <0.0001). Additionally, at week 32, the mean changes in HbA1c from baseline were −2.03% for the mazdutide group and −1.84% for the semaglutide group, while the mean percentage reductions in body weight from baseline were 10.29% and 6.00%, respectively (both P-values <0.05). The overall safety profile of mazdutide during the study was consistent with previous clinical trials, with no new safety signals identified. Gastrointestinal adverse reactions were the most common adverse events, mostly mild or moderate in severity. The clinical study data is planned to be presented at future academic conferences or published in journals.

Qingpu Biotech QP-6211 Project Completes Enrollment of All Subjects in the Second Phase III Clinical Trial

On October 22, 2025, Nanjing Qingpu Biotechnology Co., Ltd. (hereinafter referred to as "Qingpu Bio"), a biopharmaceutical company focused on the development of non-opioid analgesic new drugs, is pleased to announce that its self-developed long-acting analgesic new drug QP-6211 has completed the enrollment of all subjects in the second Phase III clinical trial for unilateral hallux valgus corrective surgery. To date, Qingpu Bio has completed the enrollment of all subjects (a total of 500 cases) in the two Phase III clinical trials of QP-6211 ahead of schedule and will accelerate the New Drug Application (NDA) process for QP-6211 in China. The company looks forward to providing clinicians with a new generation of long-acting, potent, and safe analgesic options as soon as possible, bringing pain relief benefits to over 90 million surgical patients in China. QP-6211 is the third long-acting product in Qingpu Bio's series of non-opioid analgesic new drug pipelines, developed based on Qingpu’s proprietary sustained-release injectable platform for postoperative pain relief or various refractory pain conditions. QP-6211 has successfully completed one Phase I and two Phase II clinical trials and is currently undergoing two Phase III clinical studies, with plans to enter the NDA stage soon. In the future, it is expected to become the world’s first 3-7 day long-acting formulation of its molecular type.

NCR201 by Zhongsheng Suyuan Creates a Miracle in Three Months, World's First Functional Cure for Parkinson's Disease

Recently, NCR201 Injection [induced pluripotent stem cells (iPSC) derived dopaminergic progenitor cells (iDAP)] developed by Zhongsheng Suyuan has achieved a major clinical breakthrough – a 37-year-old female patient who has been battling EOPD for nearly 15 years achieved "functional cure" just three months after receiving the treatment! This is the world's first reported milestone event of an EOPD patient achieving functional cure, marking a historic advancement in the field of Parkinson’s disease treatment. The patient underwent transplantation therapy with "NCR201 Injection" via robot-assisted stereotactic minimally invasive surgery on June 11. After three months post-surgery, comprehensive evaluations confirmed preliminary functional cure, with significant improvements in multiple key indicators. The success of this EOPD patient is not an isolated case. Existing clinical data shows that NCR201 has demonstrated positive and consistent efficacy in multiple PD subjects. Results indicate that nine months after transplantation, the “off periods” disappeared in several PD patients, PET-DAT signal for midbrain dopamine function increased by up to over 400%, oral dopamine dosage decreased by up to 38.6%, and various metrics outperformed historical data from Bayer-BlueRock's similar product, highlighting the enormous potential of NCR201 in the global Parkinson’s disease treatment landscape.

RiboBio's Small Nucleic Acid Drug RBD1016 for Treating Hepatitis D Virus Infection Granted Orphan Drug Designation by EMA

On October 24, 2025, Suzhou Ribo Life Science Co., Ltd. ("Ribo Life Science") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") jointly announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to their small interfering RNA (siRNA) candidate drug RBD1016 for the treatment of Hepatitis Delta Virus (HDV) infection. The safety, efficacy, and long-lasting effects of Ribo Life Science's self-developed RiboGalSTARTM liver-targeting delivery platform have been validated through multiple clinical studies, including RBD1016 for HDV indications, which is currently advancing globally in Phase II clinical trials for both hepatitis B and hepatitis D. Orphan Drug Designation provides innovative drugs with an optimized regulatory pathway and commercial incentives, allowing them to benefit patients more quickly.

LX101, the Gene Therapy Product of Langxin Biotechnology, Presents Latest Phase III Clinical Data at the American AAO Conference: Efficacy and Safety Further Validated

On October 19, 2025, at the 129th annual meeting of the American Academy of Ophthalmology (AAO), Langxin Biologics presented for the first time in a special report the latest progress of its core gene therapy product LX101 in the China Phase III confirmatory clinical trial targeting inherited retinal dystrophy (IRD). LX101 Injection, developed by Langxin Biologics, is an AAV-based gene therapy that uses adeno-associated virus serotype 2 (AAV2) to carry the normal RPE65 gene. It specifically identifies and transfects diseased retinal pigment epithelial cells, enabling continuous and high-efficiency expression of the RPE65 protein, which patients lack, restoring normal visual cycling and improving visual function. The LX101 STAR study (NCT07054632) is China’s first multi-center, randomized controlled Phase III gene therapy trial for inherited retinal dystrophy (IRD). This clinical trial was conducted across multiple top research centers in China, enrolling 30 participants. Study results showed that after 12 months of a single treatment with LX101, participants experienced statistically and clinically significant improvements in visual function, achieving the pre-specified primary endpoint. Meanwhile, LX101 demonstrated good safety and tolerability both locally and systemically. This achievement marks a breakthrough from "0 to 1" in the field of ophthalmic gene therapy in China, bringing new hope of restoring vision to IRD patients. Additionally, long-term follow-up data from a two-year Phase I study confirmed that LX101 provides sustained efficacy and excellent safety. In summary, LX101 has the potential to offer a groundbreaking treatment option for Chinese patients with IRD related to RPE65 mutations, addressing unmet clinical needs in this area.

Harbour BioMed Launches First Fully Human HCAb Generation Model, Empowering Next-Generation Biologic Drug Development

On October 28, 2025, the "Intelligence Illuminates HBM Shines" HBM Global R&D Day event was successfully held in Shanghai, China. During the event, HBM officially launched its first fully human AI HCAb model driven by the Hu-mAtrIx™ artificial intelligence platform — a fully human heavy-chain antibody (HCAb) generation and screening model. This model is based on proprietary data from HBM's Harbour Mice® platform, integrating a fine-tuned large language model (LLM) for sequence generation, supplemented by high-precision AI classification and drug-likeness prediction models. Unlike traditional screening methods, this platform achieves a closed-loop process of AI design, intelligent screening, and wet-lab validation. The HBM HCAb generation model is built on 9 million NGS HCAb sequences and vast public databases, fine-tuning a protein large language model to enable AI to generate high-potential HCAb candidate sequences from scratch and optimize them further for target-specific HCAbs. The HCAb sequence generation model can produce a higher order of magnitude of candidate sequences and significantly improve success rates. The AI HCAb drug-likeness prediction model meets wet-lab validation standards on key metrics such as HCAb stability, solubility, and aggregation.

Baiyang Pharmaceutical's First Precision Radiotherapy Center for Brain Tumors Signed and Established, Accelerating the Commercialization of Radiotherapy

On October 23, 2025, Baiyang Pharmaceutical (301015.SZ) signed a strategic cooperation agreement with Peking University International Hospital to jointly build a precision radiotherapy center. This center will be located at Peking University International Hospital and will rely on the ZAP-X Mars Boat radiosurgery robot operated by the company (hereinafter referred to as "ZAP-X") to create a high-level radiotherapy platform focused on the "special disease, special treatment" of brain tumors. By optimizing precise radiotherapy scenarios for brain tumors, it aims to provide innovative radiotherapy solutions for millions of brain tumor patients. The radiotherapy center being built this time will introduce what is known as a "revolutionary" breakthrough in the field of cranial radiotherapy.”The ZAP-X technology significantly enhances the precision and safety of radiotherapy for brain tumors. With the world’s first dual-gantry spherical structure, the X-rays emitted by ZAP-X can target the tumor area from thousands of non-coplanar angles, effectively eradicating the tumor while protecting the surrounding healthy brain tissue. The device also features innovative technologies such as sub-millimeter isocenter accuracy and real-time dose imaging dual monitoring, providing multiple layers of assurance for precise and safe radiotherapy. Leveraging its advantages in precise radiotherapy for brain tumors, ZAP-X has been approved for marketing in 24 countries and regions worldwide, with over 5,000 clinical treatments completed.

TowardPi's Domestically Produced Micro Axial Flow Pump vs VA-ECMO: Results of the Multicenter, Randomized Controlled Trial PERSIST III Presented at the U.S. TCT Conference

Recently, at the 37th Transcatheter Cardiovascular Therapeutics (TCT) conference held in San Francisco, USA, Professor Ge Junbo, academician of the Chinese Academy of Sciences and professor at Zhongshan Hospital of Fudan University, released the results of the PERSIST III clinical study on behalf of the research team. The PERSIST III study (NCT06853470) is a large-scale prospective, multicenter, randomized controlled, non-inferiority study comparing mAFP and VA-ECMO. Led by Academician Ge Junbo from Zhongshan Hospital of Fudan University and Professor Chen Yundai from the First Medical Center of the Chinese People's Liberation Army General Hospital, the study was conducted across 19 centers in China and included 222 patients with complex coronary artery disease, severe heart dysfunction (left ventricular ejection fraction LVEF ≤ 35%), requiring coronary revascularization, and at high risk for percutaneous coronary intervention (PCI). During PCI procedures, either the domestically produced mAFP SynFlow® 3.0 or VA-ECMO was used for hemodynamic support. The primary endpoint was the incidence of major adverse events (MAE) within 30 days post-surgery to compare the clinical efficacy of the two devices. This study is the first randomized controlled trial to directly compare the clinical efficacy of mAFP and VA-ECMO in high-risk PCI, demonstrating that the domestically produced mAFP SynFlow® 3.0 is non-inferior to VA-ECMO in terms of MAE occurrence within 30 days post-surgery in high-risk PCI patients with severe heart dysfunction (LVEF ≤ 35%) and complex coronary artery disease. The use of SynFlow® 3.0 was associated with lower intraoperative blood transfusion rates, shorter hospital stays, and fewer device-related adverse events. The SynFlow® 3.0 Percutaneous Transvalvular Ventricular Assist System, independently developed by Fengkaili Medical Devices (Shanghai) Co., Ltd., is the first interventional ventricular assist product in China to enter the NMPA Innovative Medical Device Special Approval Program.

Changde Medical® EF-Lumber® Peripheral Drug-Eluting Stent Completes Pre-Market Clinical Trial Enrollment

Recently, Shanghai Changde Medical Technology Co., Ltd. (hereinafter referred to as "Changde Medical®") announced the completion of patient enrollment for the pre-market clinical trial of its self-developed EF-Lumber® Peripheral Drug-Eluting Stent. This clinical trial is a prospective, multi-center, randomized controlled study led by Professor Xiangchen Dai from Tianjin Medical University General Hospital and Professor Lianrui Guo from Xuanwu Hospital, Capital Medical University. The aim is to evaluate the safety and efficacy of the EF-Lumber® Peripheral Drug-Eluting Stent in treating femoropopliteal artery stenosis or occlusive lesions. The EF-Lumber® Peripheral Drug-Eluting Stent is designed based on the anatomical features and biomechanical environment of the femoropopliteal artery: it adopts a composite structure with a closed-loop at the proximal end and an open-loop at the distal end — the proximal closed-loop enhances support and precise positioning, ensuring stable anchoring after implantation; the distal open-loop improves compliance, better conforming to the tortuous morphology of the femoropopliteal artery. The drug coating consists of paclitaxel and highly biocompatible fluorides, achieving targeted sustained release through gradient spraying technology. This maintains long-term local drug concentration at lower drug loads while reducing systemic toxicity risks, balancing efficacy and safety. Additionally, the stent is equipped with an innovative four-axis delivery system that optimizes push stability and deliverability, efficiently addressing the implantation needs of complex calcified and tortuous lesions. EF-Lumber® has previously received approval from the National Medical Products Administration (NMPA) to enter the special review process for innovative medical devices ("green channel"). Its future market entry is expected to fill the gap for domestically produced femoropopliteal artery drug-eluting stents, providing clinicians with solutions better suited to patients' anatomical characteristics and lesion features.

VirtuMed's Star Navigation Surgical Navigation System Lands in Jakarta, Indonesia, Successfully Assisting Neurosurgery Experts in Completing Two UBE Spinal Surgeries

Recently, after obtaining certification, Wezhu Zhiyuan's Xinghang Orthopedic Surgery Navigation System successfully completed "system installation-professional training-clinical activation" at RUMAH SAKIT JAKARTA Hospital in Jakarta, Indonesia. It successfully assisted the neurosurgical team in completing two high-precision UBE spinal surgeries. As a representative project of the Sino-Swiss Medical and Health International Innovation Platform (Swissmed.tech) to promote cross-border medical technology transfer, this marked the first time that the system achieved full-process implementation from exhibition to clinical use in Southeast Asia since participating in the "Intelligent Medicine International Education Training Innovation Development Forum" last December. This signifies that China's smart surgical solutions are now formally and deeply involved in the upgrading of Southeast Asia's healthcare system, serving as another proof of the Sino-Swiss innovation platform's efforts in promoting cross-border technology transfer, and highlighting the platform's "innovation incubation-global deployment" dual empowerment value. This collaboration not only represents single-point technology export but also establishes a "Sino-Swiss platform resource alignment + Chinese technology implementation + local healthcare upgrade" trinity model. From technical exhibitions at international forums to on-site installations and clinical applications in overseas hospitals, the company is gradually achieving a transition from "going global" to "taking root." In the future, Wezhu Zhiyuan Healthcare will continue to deepen its cooperation with the Swissmed.tech international platform to promote more innovative medical technologies serving patients and doctors worldwide.

Bioheart's Iberis RDN System Registered in Switzerland, Adding a Key Piece to Global Layout

Recently, the Platypus Iberis Renal Denervation (RDN) System successfully completed local registration in Switzerland and was clinically applied for the first time in the country by the University Hospital Basel. This surgery, performed on a patient with hypertension using a transradial minimally invasive approach, marks the official entry of this innovative Chinese medical device into a core European clinical institution, opening a new phase of local application. As the world's only RDN product supporting both transradial and femoral artery access, the Platypus Iberis system has obtained EU CE certification and achieved the first commercial applications in multiple countries including Germany, Spain, and Italy. The system’s introduction to the University Hospital Basel—a leading institution with approximately 40,000 annual patient visits and one of Europe’s highest volumes of cardiovascular interventions—carries triple milestone significance: ① Demonstrating the reliability of innovative Chinese medical devices in mainstream European clinical settings; ② Providing European patients with uncontrolled hypertension a new treatment option combining "minimally invasive" and "long-term efficacy"; ③ Promoting the standardized global application of RDN technology, contributing to the therapeutic goal of "24/7 blood pressure reduction and sustained benefits."

Yisheng Bio GMP-grade IL-3 Successfully Approved for FDA DMF Filing

Recently, the GMP-grade recombinant human interleukin-3 (IL-3) protein independently developed by Yesheng Biotechnology successfully passed the Drug Master File (DMF) registration with the U.S. Food and Drug Administration (FDA), with the registration number: MF042688. GMP-grade cytokines refer to cytokine products manufactured entirely in accordance with the Good Manufacturing Practice (GMP) standards. Their core characteristics are "controllable quality, safety compliance, and suitability for pharmaceutical/medical device research and production," distinguishing them from research-grade cytokines used only for laboratory studies. To meet the needs of the cell therapy drug development stage, Yesheng Biotechnology developed GMP-grade recombinant human IL-3 and conducted comprehensive quality control tests to ensure strict standards of purity, activity, safety, and consistency. Yesheng's GMP-grade recombinant human IL-3 protein boasts advantages such as high purity, ultra-low endotoxin levels, batch-to-batch consistency, compliance, and being animal origin-free.

N1 Life Achieves FDA Regulatory Milestone, Opens Innovative Drug Delivery Technology Collaboration Opportunities to Pharmaceutical Partners

Recently, N1 Life, a Stanford University spin-off company specializing in drug delivery technology, has reached a milestone breakthrough — its core product "METATIDE" from the Absotride® peptide technology platform has successfully registered its Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). This first-of-its-kind peptide technology represents a significant advancement in the field of transdermal and topical drug delivery, offering pharmaceutical companies an innovative solution to enhance drug penetration through biological barriers. The successful DMF registration with the FDA marks a key step in the company’s strategy to transform cutting-edge scientific research into globally competitive products. Moving forward, N1 Life will continue to focus on advancing transdermal technologies while collaborating with industry partners both domestically and internationally to drive technological innovation in topical medications and functional skincare, delivering more efficient, safer, and personalized beauty and health solutions to consumers worldwide. With the completion of the DMF registration, N1 Life is actively seeking partnerships with pharmaceutical and biotechnology companies interested in incorporating this permeation-enhancing technology into their drug development programs. The company offers collaborative development support, technical consulting, and flexible commercial arrangements.

Innovent Biologics and Takeda Pharmaceutical Reach Global Strategic Collaboration to Accelerate Next-Generation IO and ADC Therapies to Global Markets

San Francisco, USA, and Suzhou, China, October 22, 2025 — Innovent Biologics Group (HKEX: 01801) announced a significant global strategic collaboration with Takeda Pharmaceutical Company (Takeda, Tokyo Stock Exchange: 4502; New York Stock Exchange: TAK) to jointly accelerate the global development of Innovent's next-generation IO and ADC therapies. This partnership aims to create groundbreaking cancer treatment solutions for the benefit of patients worldwide. Innovent Biologics and Takeda will co-develop IBI363 (PD-1/IL-2α-bias), a next-generation cornerstone IO therapy, on a global scale and co-commercialize it in the United States. Takeda will lead the related efforts under a joint governance framework and coordinated development plan. Additionally, Innovent has granted Takeda commercial rights to IBI363 outside Greater China and the United States. This collaboration will leverage the core synergies of both parties to expedite the global development of Innovent’s IO and ADC pipeline drugs, including: 1) IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein currently in Phase III clinical trials, which has demonstrated robust and broad-spectrum anti-tumor activity across multiple studies, positioning it as a potential next-generation cornerstone IO therapy; 2) IBI343, a best-in-class CLDN18.2 ADC also in Phase III clinical trials; and 3) IBI3001, a first-in-class EGFR/B7H3 bispecific ADC currently in Phase I clinical trials. Innovent Biologics will receive an upfront payment of $1.2 billion (including $100 million in premium strategic equity investment) and potential milestone payments, with the total transaction value reaching up to $11.4 billion. Innovent will also be entitled to sales royalties.

KingMed Diagnostics and The Chinese University of Hong Kong, Shenzhen Reach Strategic Cooperation to Jointly Promote the Innovative Development of Intelligent Medicine in the Greater Bay Area

On October 25, 2025, at the International Intelligent Medical Innovation Conference in Shenzhen (CUHK) co-hosted by the School of Medicine and CUHK-Shenzhen Hospital of The Chinese University of Hong Kong (Shenzhen), KingMed Diagnostics officially signed a strategic cooperation agreement with The Chinese University of Hong Kong (Shenzhen). Both parties will cooperate in building the Shenzhen Clinical Testing and Pathological Diagnosis Center, a Medical Artificial Intelligence and Data Research Platform, and developing a medical data product system, jointly promoting the innovative development of intelligent medicine in the Greater Bay Area. As a Sino-foreign cooperative research university approved by the Ministry of Education, The Chinese University of Hong Kong (Shenzhen) features internationalization, college system, and interdisciplinary studies. It boasts an international education system, strong research capabilities and expert teams, nationally strategic disciplines (Hetao College), a global public health policy research team, and core advantages such as policy benefits from the Hetao Shenzhen-Hong Kong Cooperation Zone (cross-border data, technology transformation pilot). KingMed Diagnostics is the leader in China's third-party medical testing industry, possessing large samples and big data in pathology, proteomics, genomics, etc., providing massive medical data and clinical scenario support for partners. In terms of industry-university-research transformation, it has established industry-university-research cooperation with over 210 hospitals, universities, and scientific research institutes, successfully exploring various models of achievement transformation. This powerful collaboration between the two parties represents an important cross-sector cooperation in the medical field of the Greater Bay Area. It not only helps to improve the clinical testing and pathological diagnosis level in the Greater Bay Area and promote the application of medical artificial intelligence technologies but also facilitates the sharing and coordination of medical data and the cultivation of outstanding medical talents, injecting new momentum into the innovative development of medicine in the Greater Bay Area. Both parties will fully leverage their respective strengths to jointly promote the implementation and application of cooperative projects, making greater contributions to the innovative development of medicine in the Greater Bay Area and even throughout China.

Safu Pharmaceuticals and Shenxi Bio Reach Strategic Cooperation Agreement

On October 21, 2025, under the witness of Mr. Yin Jianguo, Chairman of BioBAY, the strategic cooperation signing ceremony between Beijing Safu Pharmaceutical Research Institute Co., Ltd. ("Safu Pharma") and Suzhou Neuxcell Biopharmaceuticals Co., Ltd. ("Neuxcell Bio") was held at Suzhou Safu. This marks a new chapter of in-depth collaboration and shared development in the field of innovative drug research and development for both parties. Neuxcell Bio is a company mainly engaged in the research of treatments for nerve injury and neurodegenerative diseases. Relying on its leading position in CNS innovative therapy research, it possesses breakthrough technology platforms and R&D pipelines. Safu Pharma, with its technical platforms and expert team in the one-stop non-clinical research field of innovative drugs, has established a distinctive research system in the psychiatric and neurological disease areas. The achievement of this strategic cooperation will fully leverage the professional advantages of both parties in the psychiatric and neurological disease fields. Through resource complementation and advantage superposition, they will jointly tackle key technical challenges in CNS drug research and development, injecting new momentum into the advancement of China's neurological disease treatment field.

YouSiDa Signs Exclusive OEM Cooperation Agreement with Pakistan's Leading Medical Enterprises to Build a New Ecosystem for Local Production and Diagnostics

On October 7, 2025, Youthink Biotech officially signed a Memorandum of Understanding (MoU) with three public health institutions in Pakistan and entered into an exclusive OEM cooperation agreement with a leading medical company in Pakistan to promote the localized production of molecular POCT diagnostic products in Pakistan. The partner is a leader in Pakistan's healthcare industry, with businesses covering in vitro diagnostics, pharmaceuticals, vaccines, and more. It has business operations in Iran, Afghanistan, and other regions, boasting an extensive customer network and market resources. The collaboration will focus on product registration and clinical validation, technology transfer and localized production, as well as market synergy and exclusive protection. This partnership brings together Youthink’s technological advantages in the molecular POCT diagnostics field and the local partner’s capabilities to jointly build an innovative platform integrating R&D, production, and talent development, thereby enhancing and achieving comprehensive coverage of diagnostic capabilities across Pakistan.

SINOVAC Biotech and ZhiXiang Biologics Reach Cooperation on Biopharmaceutical Development

Recently, ZhiXiang Bio and Sinobioway Biomedicine Co., Ltd. (referred to as: Sinobioway Pharmaceutical, stock code: 688136.SH) officially signed a strategic cooperation agreement. Both parties will collaborate on the development of macromolecular drugs. Li Zhi, Chairman of ZhiXiang Bio, stated: "This cooperation is not only about advancing projects but also represents the strategic complementation and integration of both parties' strengths. ZhiXiang Bio will fully leverage its core advantages in the full-process development and commercial production of macromolecular drugs, committing to accelerate the high-quality implementation of the project. We will join hands with Sinobioway Pharmaceutical to explore international markets and provide global patients with higher quality biopharmaceutical options." In the future, Sinobioway Pharmaceutical will seize market opportunities, expedite its internationalization process, and advance towards becoming an innovative multinational biopharmaceutical enterprise. ZhiXiang Bio also looks forward to relying on its already operational production capacity of over 100,000 liters, along with an efficient, flexible, and scalable production system, to provide a solid guarantee for the high quality, efficiency, and stability of the project's supply. This will further consolidate its commitment as a trusted partner in the industry.

Suzhou Tery Pharmaceutical Wins First Prize of the 10th Jiangsu Provincial Pharmaceutical Science and Technology Progress Award

On October 16, 2025, the "Research on the Small Molecule Targeted Anticancer Drug Nilotinib," independently developed by Tery Pharmaceutical Co., Ltd., won the first prize of the 10th Jiangsu Provincial Pharmaceutical Science and Technology Progress Award. The nilotinib capsule project of Tery Pharmaceutical achieved several "firsts" in China and even globally during its R&D process: it obtained two domestic patents and three PCT patents; it is currently the only nilotinib API product in the world to be successfully registered simultaneously in China, the United States, Europe, and Canada; it is the first drug to successfully challenge a patent and gain approval since the implementation of China’s drug patent linkage system; it was the first generic formulation to launch in the U.S.; it was the first generic formulation to launch in Canada; the nilotinib API was the first in China to obtain a CEP certificate; it was the company's first formulation product submitted for EU registration; and both the nilotinib API and formulation achieved commercial success in their first year on the market. The first prize of the Jiangsu Provincial Pharmaceutical Science and Technology Progress Award fully recognizes and encourages Tery Pharmaceutical's achievements in innovative drug development, key technological innovation, intellectual property construction and operation, product internationalization, and commercialization. In the future, the company will continue to increase investment in innovation and develop high-quality drugs to meet unmet health needs, striving to become the most valuable and trustworthy pharmaceutical enterprise.

Zhongsheng Traceability Ranks Among "Top 100 Innovative Seed Enterprises in China's Pharmaceutical Industry 2025"

Recently, the much-anticipated "Top 100 Seed Enterprises in China's Pharmaceutical Innovation 2025" list was officially released. Zhongsheng Suyuan stood out among numerous innovative companies with its profound technical expertise in the iPSC field, systematic patent layout, and several globally competitive clinical breakthroughs, successfully making it onto the list. Zhongsheng Suyuan focuses on developing widely accessible iPSC-derived cell therapy products. Guided by clinical needs, the company has taken the lead in establishing a rich R&D pipeline across three major areas: anti-inflammatory repair, regenerative medicine, and tumor immunotherapy, all centered around the iPSC technology platform. Based on the core technologies of these pipelines, the company has systematically built a comprehensive portfolio of domestic and international invention patents covering iPSC reprogramming, directed differentiation, production processes, and key raw materials, creating a solid intellectual property barrier to support continuous innovation and product development.